Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but >50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD), which remains the most important complication after HTC.

Classically, the most effective strategies to prevent GVHD have not improved survival; therefore, the new strategies are being sought.

This study is designed in two phases: the main objective for phase I study is the more suitable dose for ixazomib search. Phase II study is designed to evaluate the efficacy of ixazomib at the doses stablished in phase I.

Study Overview

• Status: Active, not recruiting
• Conditions: Multiple Myeloma; Hematopoietic Stem Cell Transplantation
• Intervention / Treatment: Drug: Ixazomib; Drug: Tacrolimus; Drug: Sirolimus; Drug: Any prophylaxis for GVHD

Detailed Description

The study design is based on a phase I / II trial in eight Spanish hospitals.

In the phase I, a number of 3 to 12 patients will be included to evaluate the optimal dose of ixazomib in combination with sirolimus and tacrolimus.

In the phase II, a total number of 130 patients will be randomized to receive ixazomib or the best medical recommendation added in order to evaluate the efficacy of ixazomib. This patients who will receive any prophylaxis for GVHD, except those patients who received antithymocyte globulin , cyclophosphamide or any T depletion protocol in vitro or in vivo.

• Study Type: Interventional
• Enrollment (Estimated): 142
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Jose-Antonio Perez-Simon, MD-PhD; Phone Number: 0034955013414; Email: josea.perez.simon.sspa@juntadeandalucia.es
• Study Contact Backup: Name: Clara Rosso, MD; Phone Number: 0034955013414; Email: claram.rosso.sspa@juntadeandalucia.es

Study Locations

• Spain
  • Badalona, Spain
    • ICO- Hospital Germans Trias i Pujol
  • Barcelona, Spain
    • Hospital Clinic de Barcelona
  • Barcelona, Spain
    • Hospital de La Santa Creu i Sant Pau
  • Barcelona, Spain
    • Hospital Universitario Vall d´Hebron
  • Madrid, Spain, 28034
    • Hospital Universitario Ramon y Cajal
  • Salamanca, Spain
    • Hospital Clinico Universitario Salamanca
  • Sevilla, Spain, 41013
    • Hospital Universitario Virgen del Rocío
  • Valencia, Spain
    • Hospital Clínico Universitario de Valencia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female patients 18 years or older.
2. Patients on the day +100 +/- 20 days who have received an allogeneic transplant with myeloablative or reduced intensity conditioning peripheral blood allogeneic stem cell transplantation.
3. Patients who have received a hematopoietic bone marrow transplant hematopoietic progenitors of peripheral blood from histo / compatible donor as definition accepted by protocol.
4. Patients receiving any prophylaxis for GVHD, except for antithymocyte globulin, cyclophosphamide or any in vitro or in vivo depletion protocol.
5. Voluntary written consent must be given before performance of any study related procedure.
6. Female patients who accomplish with requisitions for not possibility of pregnancy (menopausal, effective methods of contraception), as detailed by protocol.
7. Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2.

8. Patients must meet the following clinical laboratory criteria:

   • Absolute neutrophil count 1,000/mm3 and platelet count 75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment.
   • Total bilirubin 1.5 the upper limit of the normal range .
   • Alanine aminotransferase and aspartate aminotransferase 3 upper limit of the normal range.
   • Calculated creatinine clearance 30 mL/min.
9. Ability to swallow and tolerate oral medication.
10. Absence of gastrointestinal symptoms that precludes oral intake and absorption.
11. Off antibiotics and amphotericin B formulations, voriconazole or other anti-fungal therapy for the treatment of active proven, probable or possible infections.
12. Ability to understand the nature of this study and give written informed consent.

Exclusion Criteria:

1. Female patients who are lactating or have a positive serum pregnancy test during the screening period.
2. Major surgery within 14 days before enrollment.
3. Central nervous system involvement with malignant cells.
4. Uncontrolled infection within 14 days before study enrollment.
5. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
6. Systemic treatment, within 14 days before the first dose of ixazomib, with strong Cytochrome P450, family 3, subfamily A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
7. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
8. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
9. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
10. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
11. Patient has Grade 1 with pain or ≥ grade 2 with or without pain peripheral neuropathy.
12. Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
13. Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not.
14. Active Graft versus host disease at the time of inclusion: patients are allowed to be included if acute Graft-versus-host Disease is in complete remission and are receiving systemic steroids at < 0.25 mg / kg.
15. Active hematologic malignancy at the time of inclusion.
16. Active microangiopathy at the time of inclusion (according to International Working Group criteria).
17. Gastrointestinal disease or procedure than can interfere with oral absorption , intolerance to the ixazomib or difficulty to swallow.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day. Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo. Starting Dose of Ixazomib according to phase I.	Drug: Ixazomib; Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.; Other Names: X16082; Drug: Tacrolimus; Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.; Other Names: Prograf; Drug: Sirolimus; Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.; Other Names: Rapamune; Drug: Any prophylaxis for GVHD; Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.; Other Names: Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any in vitro or in vivo.
Other: Control group; Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.	Drug: Tacrolimus; Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.; Other Names: Prograf; Drug: Sirolimus; Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.; Other Names: Rapamune; Drug: Any prophylaxis for GVHD; Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.; Other Names: Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any in vitro or in vivo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximun tolerated dose	Maximun tolerated dose of the ixazomib in combination with sirolimus and tacrolimus in patients following allogeneic stem cell transplantation for the phase I study will be determinated	3 months after transplantation (a total of 3 cycles of 28 days length of study treatment)
Efficacy of ixazomib for phase II study	Presence of moderate plus severe Chronic Graft-versus-host Disease according to NIH scale in patients receiving the maximum tolerated dose.	9 months after transplantation (a total of 9 cycles of 28 days length of study treatment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event immune recovery for the phase I study	Quantification of time of event immune recovery in patients exposed and not exposed to ixazomib.	The post-transplant days +180, +270, +365, +545, +730
Event free survival for phase II study.	Quantification of time of event free survival for patients receiving the maximum tolerated dose.	Just after the time of transplantation and 1 and 2 years after transplantation
Event immune recovery for phase II study.	Quantification of time of event immune recovery in patients exposed and not exposed to ixazomib.	The post-transplant days +180, +270, +365, +545, +730
Exposure to immunosuppressive treatment for phase II study.	Evaluation of needs of additional permitted immunosuppressive treatment administered as concomitant medication	1 and 2 years after transplantation.
Overall disease free survival for phase II study	Quantification of time of overall survival after study treatment	2 years after transplantation.
Serious adverse event for phase II study	Describe the serious adverse event notified during the study	1 and 2 years after transplantation
Risk of moderate or severe GVHD for phase II study	To evaluate the risk of moderate or severe GVHD according to the NIH scale	2 years after transplantation
Differences among patients receiving a reduced-intensity and myeloablative conditioning regimen for phase II study.	To evaluate differences in terms of chronic GVHD and treatment tolerance	1 and 2 years after transplantation

Collaborators and Investigators

• Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Investigators: Principal Investigator: Jose-Antonio Perez-Simon, MD-PhD, Hospitales Universitarios Virgen del Rocío

Study record dates

Study Major Dates

• Study Start (Actual): May 16, 2017
• Primary Completion (Actual): January 11, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: April 4, 2017
• First Submitted That Met QC Criteria: July 18, 2017
• First Posted (Actual): July 21, 2017

Study Record Updates

• Last Update Posted (Actual): March 20, 2024
• Last Update Submitted That Met QC Criteria: March 18, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Ixazomib
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lung Diseases; Hematologic Diseases; Bronchial Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Lung Diseases, Obstructive; Neoplasms, Plasma Cell; Bronchitis; Bronchiolitis Obliterans; Bronchiolitis; Organizing Pneumonia; Multiple Myeloma; Graft vs Host Disease; Bronchiolitis Obliterans Syndrome; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Protease Inhibitors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Calcineurin Inhibitors; Cyclophosphamide; Ixazomib; Tacrolimus; Sirolimus; Antilymphocyte Serum
• Other Study ID Numbers: X16082

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Anonymized data for primary and secondary variables is planned to be shared with all participants within 6 months of data completion.
• IPD Sharing Time Frame: 6 months after data completion
• IPD Sharing Access Criteria: Investigators participating in the study until the final publication is done
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No